Le Lézard
Classified in: Health
Subjects: PDT, TDS, FDA

Tivic Health Receives FDA 510(k) Clearance To Market ClearUPtm To Treat Sinus Pain Associated With Allergic Rhinitis/Hay Fever


SAN FRANCISCO, Jan. 3, 2019 /PRNewswire/ -- Tivic Health Systems Inc. today announced that ClearUP Sinus Pain Relief, a first-in-class bioelectronic treatment for sinus pain due to allergic rhinitis (hay fever), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). ClearUP is an over-the-counter (OTC) device that provides consumers with a simple, non-invasive and drug-free option to relieve sinus pain caused by various environmental allergies such as dust, mold, pollens and pet dander.

Tivic Health's ClearUP Sinus Pain Relief

ClearUP uses gentle microcurrent waveforms to provide sinus pain relief to the 40 to 60 million Americans who suffer from allergic rhinitis. Its state-of-the-art technology measures the user's unique skin properties to target the optimal treatment points. A small, handheld device, ClearUP easily glides along the outside of the nasal passages -- the cheek, nose and brow bone -- to deliver low current electrical waveforms that stimulate the nerves under the skin to help relieve sinus pain. ClearUP will be available over-the-counter without a prescription by mid-2019. 

As part of its FDA submission, Tivic Health conducted a double-blind, randomized control trial with 71 patients with sinus pain, to evaluate the effect of microcurrent waveforms on sinus pain. In this pivotal trial, it was demonstrated that after one treatment with ClearUP, three out of four users achieved sinus pain relief (74 percent). In addition, 82 percent of those who used ClearUP preferred it over their current treatment(s). The results of this trial, conducted in May 2018 at a top-tier U.S. research science center, were presented at the American Rhinologic Society Annual Meeting in October 2018.

"In line with our corporate vision to create accessible, cutting-edge solutions for chronic conditions, we are very pleased to bring to market a next generation microcurrent device that will help transform treatment for the common allergy sufferer," said Jennifer Ernst, CEO of Tivic Health. "ClearUP's FDA clearance marks a major milestone for Tivic Health and puts us on the map as an innovative leader in the field of bioelectronics and neuromodulation."

"For the many patients suffering from allergy-related sinus pain, we now have an effective treatment option that does not involve pills, a spray or nasal flush, surgery or opioids. ClearUP is an important new option that is drug-free, side-effect free and non-invasive," added Subinoy Das, MD, FACS, FARS, Chief Executive Officer and Medical Director for the U.S. Institute for Advanced Sinus Care and Research; and a member of Tivic Health's Medical Advisory Board.

Sinus sufferers are concerned about taking sinus medicine and its side effects. The company's earlier third-party research with 600 sinus pain sufferers revealed that 95 percent wanted to decrease the amount of medicines they were taking and 91 percent were concerned about side effects from their current treatments. 

ClearUP's one-button control is easy-to-use and offers three intensity levels to personalize treatment to best suit the needs of the individual. ClearUP is intended for adults only, 18+ years of age, and can be used whenever needed, up to four times a day. Each treatment session takes five minutes. ClearUP is reusable and rechargeable, and can be used at work, home or while traveling.

About Bioelectronic Technology
Bioelectronics, a $6.2 billion industry, combines biology and electrical engineering. Devices work by modulating electrical activity in peripheral and central nerves to mitigate symptoms and/or underlying causes of disease. It is being studied to treat a range of diseases including rheumatoid arthritis, drug resistant epilepsy and alcoholism. The most common bioelectronics device is the pacemaker, first introduced in 1958. In September 2018, bioelectronics was named as one of the top ten disruptive technologies by the World Economic Forum.

About Tivic Health Systems Inc.
Tivic Health Systems Inc. (Tivic Healthtm) is a bioelectronic device company dedicated to developing microcurrent therapy solutions for chronic diseases and conditions. Tivic Health's first product, ClearUPtm Sinus Pain Relief, targets sinus pain associated with allergic rhinitis.  Founded in 2016, Tivic Health is part of a $6.2B global neuromodulation industry. The team is dedicated to harnessing the power of neuromodulation for home use products, empowering people to improve their health and quality of life. For more information, visit www.tivichealth.com and follow us on Twitter at @TivicHealth and on Facebook at www.facebook.com/TivicHealth.

Media Contacts: 
Cheryl Delgreco
[email protected]
617-723-4004 

 

SOURCE Tivic Health Systems Inc.


These press releases may also interest you

at 06:00
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in...

at 06:00
65,000 Ontario hospital workers represented by the Ontario Council of Hospital Unions-CUPE (OCHU-CUPE) and SEIU Healthcare will see a 6% wage increase (3% wage increases in each of the next two years), improvements to health and dental benefits,...

at 05:29
SmartCella Holding AB today announces that Dr Ricardo Baptista has been appointed Chief Technology Officer (CTO) and Head of Procella. Ricardo is an experienced Biochemical Engineer with almost 20-years of global experience in the medical...

at 05:15
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...



News published on and distributed by: